Oncology is a big investment target – here’s what investors care about
Me-too drugs and ill-defined AI are less interesting than unmet need and AI with supporting evidence.
Pharma is making inroads into digital health, albeit slowly
Panelists highlight Roche's acquisition of Flatiron Health in February and use of AI/ML in drug development.
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
US slower than Europe, emerging markets in liquid biopsy adoption
Blood-based cancer tests have market, but more evidence may be needed to verify validity and utility.